The company focuses on chronic care, which translates into an ongoing stream of revenue from relatively concentrated global markets. Convatec's well-established footprint in the US ostomy market has paved the way to forge contracts with large group purchasing organizations, including Premier and Vizient.
Cyborg Score Rationale
ConvaTec reaffirmed its 2026 target for double-digit adjusted EPS growth and further margin expansion. Three new wound care products (ConvaNioX, ConvaFiber, ConvaVac) and other pipeline launches are planned for 2026, with ConvaNioX seen as a major long-term opportunity. Strategic momentum supported by strong product innovation pipeline.
Top Insights
Trading remained strong across all divisions with all four segments – Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care – growing as fast or faster than in the first half.
Major product launches planned for 2026 including ConvaNioX, ConvaFiber, and ConvaVac with ConvaNioX as a long-term opportunity.
Secured first US Ostomy GPO contract in over five years and extended another key contract by three years.
Management noted confidence in delivering profit growth even under a tougher US reimbursement scenario for its wound care business.
Named Competitors
Coloplast — Leading ostomy and continence care competitor
Zimmer Biomet — Medical devices and orthopedic solutions
Joerns Healthcare — Pressure relief and patient mobility
Urgo Medical — Wound care and advanced dressings
Recent Developments
(November 2025) Reaffirmed double-digit adjusted EPS growth target and narrowed 2025 organic revenue guidance to 6.0-6.5%
(October 2025) Secured first US Ostomy GPO contract in over five years
(2026 Outlook) Three new wound care products planned including ConvaNioX, ConvaFiber, ConvaVac
Open the full interactive ConvaTec Group PLC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.